Relmada Therapeutics, Inc. - Common Stock (NQ:RLMD)

3.505 -0.095 (-2.64%)

Delayed Quote Updated: 10:08 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Relmada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Dow Surges 950 Points; S&P 500 Rises 3% ↗

October 13, 2022

U.S. stocks traded higher toward the end of trading, with the Dow Jones jumping around 950 points on Thursday.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 13, 2022

Gainers

Via Benzinga

Stocks Stage Midday Comeback After Red-Hot CPI Data ↗

October 13, 2022

The market is brushing off this morning's CPI data.

Via Talk Markets

Why Is Axsome Therapeutics (AXSM) Stock Up Today? ↗

October 13, 2022

Sometimes, company shares can catch a bid when a rival gets bad news. That's happening with Axsome today as AXSM stock moves higher.

Via InvestorPlace

Gold Down 1.5%; Domino's Pizza Shares Spike Higher ↗

October 13, 2022

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 150 points on Thursday.

Via Benzinga

Relmada Stock Tumbles To 52-Week Low On Failed Depression Trial ↗

October 13, 2022

Via Benzinga

Earnings Scheduled For August 11, 2022 ↗

August 11, 2022

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 04, 2022

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...

Via Benzinga

Why Laser Photonics Shares Are Trading Higher By Around 44%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

October 13, 2022

Gainers FedNat Holding Company (NASDAQ: FNHC) shares jumped 89% to $0.4242 after dipping 34% on Wednesday.

Via Benzinga

Why Are Tech Stocks Down Today? ↗

October 13, 2022

Tech stocks aren't doing so hot on Thursday as investors react to the latest data from the Consumer Price Index (CPI) report for September.

Via InvestorPlace

Progressive, Asana And Some Other Big Stocks Moving Lower On Thursday ↗

October 13, 2022

U.S. stocks traded lower, with the Dow Jones gaining more than 100 points on Thursday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Is Relmada (RLMD) Stock Down 78% Today? ↗

October 13, 2022

Relmada Therapeutics (RLMD) stock is plummeting on Thursday as investors react to results from a Phase 3 clinical trial.

Via InvestorPlace

Relmada Tanks After 'Paradoxical Results' Undermine Depression Drug; Axsome Surges ↗

October 13, 2022

The company noted "paradoxical results" where the placebo, at times, topped the drug.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 13, 2022

Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares rose 24.6% to $0.14 during Thursday's pre-market session. The market value of their outstanding shares is at $17.1 million.

Via Benzinga

Why Relmada Therapeutics Shares Are Trading Lower By 84%; Here Are 23 Stocks Moving Premarket ↗

October 13, 2022

Gainers Laser Photonics Corporation (NASDAQ: LASE) shares rose 45% to $4.24 in pre-market trading. Laser Photonics announced that Coca-Cola recently completed the implementation of its first CleanTech...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 20, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help ↗

August 11, 2022

Today's depression drugs don't fit many patients' needs. Biotech companies may change that.

Via Investor's Business Daily

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 09, 2022

Via Benzinga

Relmada Secures FDA Fast Track Status For Depressive Disorder Candidate ↗

August 09, 2022

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ: RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder...

Via Benzinga

Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028

May 26, 2022

Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,...

Via FinancialNewsMedia

10 Biggest Price Target Changes For Monday ↗

May 09, 2022

Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading.

Via Benzinga

Relmada Therapeutics Earnings Preview ↗

May 04, 2022

Relmada Therapeutics (NASDAQ:RLMD) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy ↗

April 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Here's Why Relmada Therapeutics Shares Are Rising ↗

March 24, 2022

Relmada Therapeutics Inc (NASDAQ: RLMD) shares are trading higher by 7.2% at $25.01 after the company reported better-than-expected fourth-quarter EPS results. Relmada...

Via Benzinga

Earnings Scheduled For March 23, 2022 ↗

March 23, 2022

Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter. • First Trust NASDAQ Clean Edge Smart Grid...

Via Benzinga

Relmada Therapeutics's Earnings Outlook ↗

March 22, 2022

Relmada Therapeutics (NASDAQ:RLMD) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement....

Via Benzinga

Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential ↗

February 23, 2022

Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD....

Via Benzinga

Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally

February 24, 2022

Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept...

Via FinancialNewsMedia

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO ↗

December 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug...

Via Benzinga

Relmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate ↗

December 09, 2021

Relmada Therapeutics Inc (NASDAQ: RLMD) priced an upsized underwritten public offering of 8.82 million shares at $17.00 per share, with gross proceeds of approximately...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.